Identification
NameOctreotide
Accession NumberDB00104  (BTD00088, BIOD00088)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

Structure
Thumb
Synonyms
Octreotida
Octreotidum
Octrotide
External IDs SMS 201-995 / SMS-201-995
Product Ingredients
IngredientUNIICASInChI KeyDetails
Octreotide acetate75R0U2568I 79517-01-4XQEJFZYLWPSJOV-XJQYZYIXSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OcphylSolution500 mcgIntravenous; SubcutaneousPendopharm Division Of De Pharmascience Inc2014-05-12Not applicableCanada
OcphylSolution50 mcgIntravenous; SubcutaneousPendopharm Division Of De Pharmascience Inc2014-05-12Not applicableCanada
OcphylSolution100 mcgIntravenous; SubcutaneousPendopharm Division Of De Pharmascience Inc2014-05-12Not applicableCanada
Octreotide AcetateInjection, solution1000 ug/mLIntravenous; SubcutaneousSandoz1988-10-21Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousSandoz2014-02-04Not applicableUs
Octreotide AcetateInjection, solution200 ug/mLIntravenous; SubcutaneousSandoz1988-10-21Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousSandoz2014-02-04Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousSandoz2014-02-04Not applicableUs
Octreotide Acetate Injection - 100mcg/mlSolution100 mcgIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Octreotide Acetate Injection - 200mcg/mlSolution200 mcgIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Octreotide Acetate Injection - 500mcg/mlSolution500 mcgIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Octreotide Acetate Injection - 50mcg/mlSolution50 mcgIntravenous; SubcutaneousSandoz Canada IncorporatedNot applicableNot applicableCanada
Octreotide Acetate Omega 100mcg/mlSolution100 mcgIntravenous; SubcutaneousOmega Laboratories Ltd2004-02-26Not applicableCanada
Octreotide Acetate Omega 200mcg/mlSolution200 mcgIntravenous; SubcutaneousOmega Laboratories Ltd2004-03-11Not applicableCanada
Octreotide Acetate Omega 500mcg/mlSolution500 mcgIntravenous; SubcutaneousOmega Laboratories Ltd2004-02-26Not applicableCanada
Octreotide Acetate Omega 50mcg/mlSolution50 mcgIntravenous; SubcutaneousOmega Laboratories Ltd2004-02-26Not applicableCanada
Octreotide InjectionSolution200 mcgIntravenous; SubcutaneousTeva2008-03-06Not applicableCanada
Octreotide InjectionSolution50 mcgIntravenous; SubcutaneousTeva2014-04-18Not applicableCanada
Octreotide InjectionSolution500 mcgIntravenous; SubcutaneousTeva2008-03-06Not applicableCanada
Octreotide InjectionSolution100 mcgIntravenous; SubcutaneousTeva2008-03-06Not applicableCanada
SandostatinInjection, solution500 ug/mLIntravenous; SubcutaneousNovartis1988-10-21Not applicableUs
SandostatinInjection, solution50 ug/mLIntravenous; SubcutaneousNovartis1988-10-21Not applicableUs
SandostatinInjection, solution200 ug/mLIntravenous; SubcutaneousNovartis1998-10-21Not applicableUs
SandostatinInjection, solution100 ug/mLIntravenous; SubcutaneousNovartis1988-10-21Not applicableUs
SandostatinInjection, solution1000 ug/mLIntravenous; SubcutaneousNovartis1988-10-21Not applicableUs
Sandostatin 100mcg/mlSolution100 mcgIntravenous; SubcutaneousNovartis1989-12-31Not applicableCanada
Sandostatin 200mcg/mlSolution200 mcgIntravenous; SubcutaneousNovartis1996-12-31Not applicableCanada
Sandostatin 500mcg/mlSolution500 mcgIntravenous; SubcutaneousNovartis1989-12-31Not applicableCanada
Sandostatin 50mcg/mlSolution50 mcgIntravenous; SubcutaneousNovartis1989-12-31Not applicableCanada
Sandostatin Lar 10mgPowder10 mgIntramuscularNovartis1999-01-27Not applicableCanada
Sandostatin Lar 20mgPowder20 mgIntramuscularNovartis1999-01-27Not applicableCanada
Sandostatin Lar 30mgPowder30 mgIntramuscularNovartis1999-01-27Not applicableCanada
Sandostatin LAR DepotKitNovartis2016-07-22Not applicableUs
Sandostatin LAR DepotKitNovartis2015-02-01Not applicableUs
Sandostatin LAR DepotKitNovartis2016-07-22Not applicableUs
Sandostatin LAR DepotKitNovartis1988-11-012017-04-30Us
Sandostatin LAR DepotKitNovartis2015-02-01Not applicableUs
Sandostatin LAR DepotKitNovartis1988-11-012017-08-31Us
Sandostatin LAR DepotKitNovartis2015-02-01Not applicableUs
Sandostatin LAR DepotKitNovartis2016-07-22Not applicableUs
Sandostatin LAR DepotKitNovartis1988-11-012017-08-31Us
Sandostatin LAR Depot Demonstration KitKitNovartis1988-11-012017-08-31Us
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OctreotideInjection, solution500 ug/mLIntravenous; SubcutaneousFresenius Kabi2006-03-14Not applicableUs
OctreotideInjection, solution50 ug/mLIntravenous; SubcutaneousFresenius Kabi2006-03-14Not applicableUs
OctreotideInjection, solution200 ug/mLIntravenous; SubcutaneousFresenius Kabi2006-03-14Not applicableUs
OctreotideInjection, solution100 ug/mLIntravenous; SubcutaneousFresenius Kabi2006-03-14Not applicableUs
OctreotideInjection, solution1000 ug/mLIntravenous; SubcutaneousFresenius Kabi2006-03-14Not applicableUs
Octreotide AcetateInjection, solution1000 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2007-08-142017-02-15Us
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2005-11-14Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousMylan Institutional2011-04-01Not applicableUs
Octreotide acetateInjection1000 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousSagent Pharmaceuticals2013-12-15Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2007-08-142017-02-15Us
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousWest Ward Pharmaceutical2005-04-04Not applicableUs
Octreotide acetateInjection500 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution1000 ug/mLIntravenous; SubcutaneousSagent Pharmaceuticals2013-12-15Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2007-08-142017-02-15Us
Octreotide acetateInjection200 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution200 ug/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2005-11-23Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousMylan Institutional2011-04-01Not applicableUs
Octreotide AcetateInjection, solution1000 ug/mLIntravenous; SubcutaneousWest Ward Pharmaceutical2005-04-08Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2012-08-312017-02-15Us
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousSagent Pharmaceuticals2013-12-15Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2007-08-142017-02-15Us
Octreotide acetateInjection1000 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution100 ug/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2005-11-14Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousMylan Institutional2011-04-01Not applicableUs
Octreotide acetateInjection100 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousWest Ward Pharmaceutical2005-04-04Not applicableUs
Octreotide acetateInjection50 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide acetateInjection500 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution1000 ug/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2005-11-23Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousSagent Pharmaceuticals2013-12-15Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2012-08-312017-02-15Us
Octreotide AcetateInjection, solution200 ug/mLIntravenous; SubcutaneousSagent Pharmaceuticals2013-12-15Not applicableUs
Octreotide AcetateInjection, solution200 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2007-08-142017-02-15Us
Octreotide acetateInjection100 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution500 ug/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2005-11-14Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousWest Ward Pharmaceutical2005-04-04Not applicableUs
Octreotide acetateInjection200 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Octreotide AcetateInjection, solution200 ug/mLIntravenous; SubcutaneousWest Ward Pharmaceutical2005-04-08Not applicableUs
Octreotide AcetateInjection, solution50 ug/mLIntravenous; SubcutaneousSun Pharmaceutical Industries Limited2012-08-312017-02-15Us
Octreotide acetateInjection50 ug/mLIntravenous; SubcutaneousWockhardt2011-05-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Sandostatin LARNovartis Pharmaceuticals
Brand mixturesNot Available
Categories
UNIIRWM8CCW8GP
CAS number83150-76-9
WeightAverage: 1019.25
Monoisotopic: 1018.440480713
Chemical FormulaC49H66N10O10S2
InChI KeyDEQANNDTNATYII-OULOTJBUSA-N
InChI
InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
IUPAC Name
(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-amino-3-phenylpropanamido]-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-[(1H-indol-3-yl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
SMILES
[H][[email protected]]1(NC(=O)[[email protected]](CCCCN)NC(=O)[[email protected]@H](CC2=CNC3=C2C=CC=C3)NC(=O)[[email protected]](CC2=CC=CC=C2)NC(=O)[[email protected]](CSSC[[email protected]](NC1=O)C(=O)N[[email protected]](CO)[[email protected]@H](C)O)NC(=O)[[email protected]](N)CC1=CC=CC=C1)[[email protected]@H](C)O
Pharmacology
Indication

For treatment of acromegaly and reduction of side effects from cancer chemotherapy

Structured Indications
Pharmacodynamics

Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.

Mechanism of action

Octreotide binds to somatostatin receptors. These receptors are coupled via pertussis toxin sensitive G proteins which lead to inhibition of adenylyl cyclase. Octreotide binding to these receptors also stimulates phosphotyrosine phosphatase and activation of the Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.

TargetKindPharmacological actionActionsOrganismUniProt ID
Somatostatin receptor type 1ProteinyesNot AvailableHumanP30872 details
Somatostatin receptor type 5ProteinyesNot AvailableHumanP35346 details
Somatostatin receptor type 2Proteinyes
binder
HumanP30874 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 13.6 L [healthy volunteers]
  • 21.6 ± 8.5 L [patients with acromegaly]
Protein bindingNot Available
MetabolismNot Available
Route of elimination

About 32% of the dose is excreted unchanged into the urine.

Half lifeNot Available
Clearance
  • 7 – 10 L/hr [healthy after 100-mcg SC injection]
  • 18 L/hr [patients with acromegaly after 100-mcg SC injection]
  • 8.8 L/hr [mild renal impairment after 100-mcg SC injection]
  • 7.3 L/hr [moderate renal impairment after 100-mcg SC injection]
  • 7.6 L/hr [severe renal impairment after 100-mcg SC injection]
  • 4.5 L/hr [severe renal failure requiring dialysis after 100-mcg SC injection]
  • 5.9 L/hr [Patients with liver cirrhosis after 100-mcg SC injection]
  • 8.2 L/hr [patients with fatty liver disease after 100-mcg SC injection]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Octreotide.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Octreotide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Octreotide.Approved, Investigational
AcebutololOctreotide may increase the bradycardic activities of Acebutolol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Octreotide.Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Octreotide.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Octreotide.Approved, Vet Approved
AICA ribonucleotideThe therapeutic efficacy of Aicar can be decreased when used in combination with Octreotide.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Octreotide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Octreotide.Approved
AmiodaroneOctreotide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AnagrelideOctreotide may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideOctreotide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherOctreotide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineOctreotide may increase the QTc-prolonging activities of Asenapine.Approved
AtenololOctreotide may increase the bradycardic activities of Atenolol.Approved
AzithromycinOctreotide may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Octreotide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Octreotide.Approved, Investigational
BedaquilineOctreotide may increase the QTc-prolonging activities of Bedaquiline.Approved
BendroflumethiazideOctreotide may increase the bradycardic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Octreotide.Withdrawn
BeractantOctreotide may increase the bradycardic activities of Beractant.Approved
BetaxololOctreotide may increase the bradycardic activities of Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Octreotide.Approved, Investigational
BisoprololOctreotide may increase the bradycardic activities of Bisoprolol.Approved
BretyliumBretylium may increase the bradycardic activities of Octreotide.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Octreotide.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Octreotide.Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Octreotide.Approved
CalfactantOctreotide may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Octreotide.Withdrawn
CarteololOctreotide may increase the bradycardic activities of Carteolol.Approved
CarvedilolOctreotide may increase the bradycardic activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Octreotide.Experimental
CeritinibOctreotide may increase the bradycardic activities of Ceritinib.Approved
ChloroquineOctreotide may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineOctreotide may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideOctreotide may increase the hypoglycemic activities of Chlorpropamide.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Octreotide.Experimental
CinoxacinCinoxacin may increase the hypoglycemic activities of Octreotide.Approved, Withdrawn
CiprofloxacinOctreotide may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideOctreotide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOctreotide may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinOctreotide may increase the QTc-prolonging activities of Clarithromycin.Approved
ClonidineOctreotide may increase the bradycardic activities of Clonidine.Approved
ClozapineOctreotide may increase the QTc-prolonging activities of Clozapine.Approved
CodeineThe metabolism of Codeine can be decreased when combined with Octreotide.Approved, Illicit
CrizotinibOctreotide may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Octreotide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Octreotide.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Octreotide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Octreotide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Octreotide.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Octreotide.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Octreotide.Approved
DexmedetomidineOctreotide may increase the bradycardic activities of Dexmedetomidine.Approved, Vet Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Octreotide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Octreotide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Octreotide.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Octreotide.Illicit
DiltiazemOctreotide may increase the bradycardic activities of Diltiazem.Approved
DisopyramideOctreotide may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.Approved, Investigational
DofetilideOctreotide may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronOctreotide may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneOctreotide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilOctreotide may increase the bradycardic activities of Donepezil.Approved
DronedaroneOctreotide may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolOctreotide may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Octreotide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Octreotide.Approved
EliglustatOctreotide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Octreotide.Approved
ErythromycinOctreotide may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramOctreotide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololOctreotide may increase the bradycardic activities of Esmolol.Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Octreotide.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Octreotide.Approved, Investigational
FingolimodOctreotide may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideOctreotide may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Octreotide.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Octreotide.Withdrawn
FluoxetineOctreotide may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Octreotide.Approved, Illicit
FlupentixolOctreotide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Octreotide.Approved, Vet Approved
Gadobenic acidOctreotide may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineOctreotide may increase the bradycardic activities of Galantamine.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Octreotide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Octreotide.Approved, Investigational
GemifloxacinOctreotide may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Octreotide.Withdrawn
GliclazideOctreotide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOctreotide may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOctreotide may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Octreotide.Approved
GlyburideOctreotide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinOctreotide may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronOctreotide may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Octreotide.Withdrawn
GuanfacineOctreotide may increase the bradycardic activities of Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Octreotide.Investigational
HaloperidolOctreotide may increase the QTc-prolonging activities of Haloperidol.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Octreotide.Experimental
IbutilideOctreotide may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneOctreotide may increase the QTc-prolonging activities of Iloperidone.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Octreotide.Investigational, Withdrawn
Insulin AspartOctreotide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOctreotide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Octreotide.Approved
Insulin GlulisineOctreotide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Octreotide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Octreotide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Octreotide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Octreotide.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Octreotide.Approved
IvabradineOctreotide may increase the bradycardic activities of Ivabradine.Approved
LabetalolOctreotide may increase the bradycardic activities of Labetalol.Approved
LacosamideOctreotide may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LanreotideOctreotide may increase the hypoglycemic activities of Lanreotide.Approved
LenvatinibOctreotide may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideOctreotide may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololOctreotide may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinOctreotide may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Octreotide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Octreotide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Octreotide.Approved
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Octreotide.Approved
LopinavirOctreotide may increase the QTc-prolonging activities of Lopinavir.Approved
LucinactantOctreotide may increase the bradycardic activities of Lucinactant.Approved
LumefantrineOctreotide may increase the QTc-prolonging activities of Lumefantrine.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Octreotide.Withdrawn
MecaserminOctreotide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MesalazineMesalazine may increase the hypoglycemic activities of Octreotide.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Octreotide.Approved
MethadoneOctreotide may increase the QTc-prolonging activities of Methadone.Approved
MethyldopaOctreotide may increase the bradycardic activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Octreotide.Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Octreotide.Approved
MetipranololOctreotide may increase the bradycardic activities of Metipranolol.Approved
MetoprololOctreotide may increase the bradycardic activities of Metoprolol.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Octreotide.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Octreotide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Octreotide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Octreotide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Octreotide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Octreotide.Approved, Investigational
MoclobemideMoclobemide may increase the hypoglycemic activities of Octreotide.Approved
MoxifloxacinOctreotide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololOctreotide may increase the bradycardic activities of Nadolol.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Octreotide.Approved
NateglinideOctreotide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololOctreotide may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Octreotide.Approved, Withdrawn
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Octreotide.Investigational
NialamideNialamide may increase the hypoglycemic activities of Octreotide.Withdrawn
NilotinibOctreotide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Octreotide.Investigational
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Octreotide.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Octreotide.Withdrawn
OfloxacinOctreotide may increase the QTc-prolonging activities of Ofloxacin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Octreotide.Experimental
OlsalazineOlsalazine may increase the hypoglycemic activities of Octreotide.Approved
OndansetronOctreotide may increase the QTc-prolonging activities of Ondansetron.Approved
OuabainOuabain may decrease the cardiotoxic activities of Octreotide.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OxymetholoneOxymetholone may increase the hypoglycemic activities of Octreotide.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide.Approved, Vet Approved
PaliperidoneOctreotide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatOctreotide may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PargylinePargyline may increase the hypoglycemic activities of Octreotide.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
PasireotideOctreotide may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibOctreotide may increase the QTc-prolonging activities of Pazopanib.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Octreotide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Octreotide.Approved
PegvisomantThe risk or severity of adverse effects can be increased when Octreotide is combined with Pegvisomant.Approved
PenbutololOctreotide may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineOctreotide may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenOctreotide may increase the QTc-prolonging activities of Perflutren.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Octreotide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Octreotide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Octreotide.Withdrawn
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Octreotide.Withdrawn
PimozideOctreotide may increase the QTc-prolonging activities of Pimozide.Approved
PindololOctreotide may increase the bradycardic activities of Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Octreotide.Approved, Investigational
PirlindolePirlindole may increase the hypoglycemic activities of Octreotide.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Octreotide.Withdrawn
Poractant alfaOctreotide may increase the bradycardic activities of Poractant alfa.Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Octreotide.Approved, Investigational
PrimaquineOctreotide may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideOctreotide may increase the QTc-prolonging activities of Procainamide.Approved
PromazineOctreotide may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneOctreotide may increase the QTc-prolonging activities of Propafenone.Approved
PropranololOctreotide may increase the bradycardic activities of Propranolol.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Octreotide.Investigational
QuetiapineOctreotide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineOctreotide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineOctreotide may increase the QTc-prolonging activities of Quinine.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Octreotide.Approved
RepaglinideOctreotide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RivastigmineOctreotide may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Octreotide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Octreotide.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Octreotide.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Octreotide.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Octreotide.Approved, Vet Approved
SaquinavirOctreotide may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Octreotide.Approved
SelegilineSelegiline may increase the hypoglycemic activities of Octreotide.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Octreotide.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Octreotide.Approved, Investigational
SotalolOctreotide may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Octreotide.Approved
StanozololStanozolol may increase the hypoglycemic activities of Octreotide.Approved, Vet Approved
SufentanilOctreotide may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfadiazineOctreotide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleOctreotide may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleOctreotide may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Octreotide.Approved, Investigational
SunitinibOctreotide may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TelavancinOctreotide may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinOctreotide may increase the QTc-prolonging activities of Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Octreotide.Withdrawn
TestosteroneTestosterone may increase the hypoglycemic activities of Octreotide.Approved, Investigational
TetrabenazineOctreotide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineOctreotide may increase the QTc-prolonging activities of Thioridazine.Withdrawn
TimololOctreotide may increase the bradycardic activities of Timolol.Approved
TizanidineOctreotide may increase the bradycardic activities of Tizanidine.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Octreotide.Approved, Investigational
TolazamideOctreotide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideOctreotide may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Octreotide.Approved
ToremifeneOctreotide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Octreotide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Octreotide.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Octreotide.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Octreotide.Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Octreotide.Approved, Withdrawn
VandetanibOctreotide may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibOctreotide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Octreotide.Approved
VerapamilOctreotide may increase the bradycardic activities of Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Octreotide.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Octreotide.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Octreotide.Withdrawn
ZiprasidoneOctreotide may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolOctreotide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Nishith Chaturvedi, "Novel process for production of the somatostatin analog, octreotide." U.S. Patent US20040225108, issued November 11, 2004.

US20040225108
General References
  1. Uhl W, Anghelacopoulos SE, Friess H, Buchler MW: The role of octreotide and somatostatin in acute and chronic pancreatitis. Digestion. 1999;60 Suppl 2:23-31. [PubMed:10207228 ]
External Links
ATC CodesH01CB02 — Octreotide
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (69.7 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableIrritable Bowel Syndrome (IBS)1
1CompletedBasic ScienceBMI >30 kg/m2 / Hyperglucagonaemia1
1CompletedTreatmentDrug Interactions1
1CompletedTreatmentEnterocutaneous Fistulas / Intra-Abdominal Infections1
1CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Paraganglioma / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Merkel Cell Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor / Stage III Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma / Thyroid Gland Medullary Carcinoma1
1CompletedTreatmentHealthy Volunteer Study1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentType 2 Diabetes Mellitus1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentSmall Bowel Carcinoid Tumor1
1SuspendedTreatmentAcromegaly1
1, 2Active Not RecruitingTreatmentChronic Orthostatic Intolerance / Tachycardia1
1, 2CompletedPreventionLiver Cirrhosis / Portal Hypertension / Varices, Esophageal1
1, 2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1, 2TerminatedTreatmentCarcinoid Syndrome1
1, 2Unknown StatusTreatmentMigrainous Headache1
2Active Not RecruitingTreatmentAcromegaly1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentGastrin-Producing Neuroendocrine Tumor / Malignant Pancreatic Gastrinoma / Malignant Pancreatic Glucagonoma / Malignant Pancreatic Insulinoma / Malignant Pancreatic Somatostatinoma / Pancreatic Alpha Cell Adenoma / Pancreatic Beta Cell Adenoma / Pancreatic Delta Cell Adenoma / Pancreatic G-Cell Adenoma / Pancreatic Gastrinoma / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Neuroendocrine Tumor G1 / Pancreatic Neuroendocrine Tumor G2 / Pancreatic Polypeptide Tumor / Pancreatic Vipoma / Recurrent Pancreatic Carcinoma / Recurrent Pancreatic Neuroendocrine Carcinoma / Somatostatin-Producing Neuroendocrine Tumor / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
2Active Not RecruitingTreatmentNeoplasms, Gastrointestinal1
2CompletedSupportive CareCancer, Ovarian / Colorectal Cancers / Constipation, Impaction, and Bowel Obstruction / Extrahepatic Bile Duct Cancer / Gastrointestinal Stromal Tumors / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Nausea and Vomiting / Peritoneal Cavity Cancer / Small Intestine Cancer1
2CompletedTreatmentAbdominal wall neoplasm / Carcinomatosis / Intestinal Obstruction1
2CompletedTreatmentAcromegaly3
2CompletedTreatmentAscites / Lymphangioleiomyomatosis / Lymphangiomyomas / Pleural Effusions1
2CompletedTreatmentBMI >30 kg/m2 / Primary Insulin Hypersecretion1
2CompletedTreatmentCancers / Livers1
2CompletedTreatmentCarcinoid tumour of the gastrointestinal tract / Islet Cell Tumor / Neoplastic Syndrome1
2CompletedTreatmentCarcinoma NOS / Neuroendocrine Tumors1
2CompletedTreatmentCarcinoma, Islet Cell / Neoplasms, Pancreatic / Neuroendocrine Carcinomas / Neuroendocrine Tumors1
2CompletedTreatmentCarcinoma, Islet Cell / Neuroendocrine Carcinomas1
2CompletedTreatmentEctasia / Hereditary Haemorrhagic Telangiectasia (HHT)1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLocal Recurrent Thymoma / Primary Inoperable Thymoma1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentNeuroendocrine Carcinomas1
2CompletedTreatmentThymoma and Thymic Carcinoma1
2CompletedTreatmentAdvanced thymic carcinoma1
2Enrolling by InvitationTreatmentOctreotide / Sputum1
2Not Yet RecruitingSupportive CareMajor Liver Resection1
2RecruitingTreatmentAnemias / Hemorrhage, Gastrointestinal / Hereditary Haemorrhagic Telangiectasia (HHT)1
2RecruitingTreatmentCarcinoid Tumors1
2RecruitingTreatmentFibrosis / Hepatorenal Syndrome / Renal Failure1
2RecruitingTreatmentFistula; Salivary Duct or Gland1
2RecruitingTreatmentRecurrent Meningiomas / Resistant Meningiomas1
2TerminatedSupportive CareDiarrhea / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2TerminatedTreatmentHead and Neck Carcinoma / Islet Cell Tumor / Metastatic Cancers / Pheochromocytomas1
2TerminatedTreatmentNeuroendocrine Carcinomas1
2TerminatedTreatmentProstate Cancer1
2Unknown StatusTreatmentNeuroendocrine Carcinomas1
2WithdrawnTreatmentCarcinoid tumour of the gastrointestinal tract / Carcinoma, Islet Cell1
2, 3CompletedTreatmentAbdominal Pain (AP) / Hepatomegaly / Kidney, Polycystic / Liver Diseases / Polycystic Kidney, Autosomal Dominant / Polycystic Liver Disease (PLD)1
2, 3CompletedTreatmentRefractory Ascites / Type 2 Hepatorenal Syndrome1
2, 3RecruitingTreatmentAnemias / Angiodysplasia / Hemorrhage, Gastrointestinal / Vascular Malformations1
2, 3RecruitingTreatmentCancer, Advanced / Neuroendocrine Tumors / Well-differentiated Non-pancreatic Neuroendocrine Carcinoma1
3Active Not RecruitingTreatmentCarcinoid Tumor of the Small Bowel / Neuroendocrine Tumours1
3Active Not RecruitingTreatmentNeuroendocrine Carcinomas1
3CompletedPreventionChemotherapy-induced Diarrhea1
3CompletedSupportive CareAnal Carcinoma / Colorectal Cancers / Drug/Agent Toxicity by Tissue/Organ / Radiation Enteritis1
3CompletedSupportive CareCancer, Ovarian / Cervical Cancers / Colorectal Cancers / Diarrhea / Endometrial Cancers / Fallopian Tube Cancer / Prostate Cancer / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific / Vaginal Cancers / Vulvar Cancers1
3CompletedSupportive CareColorectal Cancers / Diarrhea1
3CompletedTreatmentAcromegaly4
3CompletedTreatmentAdvanced Hepatocellular Carcinoma1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentCarcinoid Tumors / Malignant Carcinoid Syndrome1
3CompletedTreatmentDiabetes Mellitus (DM) / Hypoglycemia1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentMetastatic Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentSymptomatic Refractory Resistant Carcinoid Disease1
3Not Yet RecruitingTreatmentPancreatic Surgery1
3RecruitingTreatmentAcromegaly2
3RecruitingTreatmentMalignant Neoplasm of Pancreas1
3TerminatedSupportive CareColorectal Cancers / Diarrhea1
3TerminatedTreatmentAcromegaly3
3TerminatedTreatmentHyperphagia / Prader-Willi Syndrome1
4CompletedPreventionDiarrhea / Neoplasms1
4CompletedSupportive CareColonic Motility Index / Occasional Constipation1
4CompletedTreatmentAcromegaly7
4CompletedTreatmentBMI >30 kg/m21
4CompletedTreatmentGastric and Esophageal Varices1
4CompletedTreatmentHaematemesis / Liver Cirrhosis / Melena / Portal Hypertension1
4CompletedTreatmentHypothalamic Obesity1
4CompletedTreatmentPancreatic Fistula1
4RecruitingPreventionAdenoma benign1
4RecruitingTreatmentAcromegaly1
4RecruitingTreatmentNeoplasms1
4TerminatedTreatmentAcromegaly1
4Unknown StatusTreatmentAcromegaly1
4Unknown StatusTreatmentVariceal Bleeding, Cirrhosis1
Not AvailableCompletedNot AvailableAcromegaly1
Not AvailableCompletedBasic ScienceBMI >30 kg/m2 / Sarcopenia1
Not AvailableCompletedBasic SciencePancreatic Fistula1
Not AvailableCompletedPreventionPeriampullary Carcinoma Resectable1
Not AvailableCompletedTreatmentDiarrhea / Human Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentPrader Willis Syndrome1
Not AvailableEnrolling by InvitationBasic ScienceDuodenal Neoplasms / Malnutrition / Neoplasms, Esophageal / Neoplasms, Pancreatic / Obese experiencing rapid weight loss / Stomach Neoplasms1
Not AvailableEnrolling by InvitationBasic ScienceMalnutrition / Neoplasms, Esophageal / Obese experiencing rapid weight loss / Stomach Neoplasms1
Not AvailableNot Yet RecruitingNot AvailableAcromegaly1
Not AvailableNot Yet RecruitingNot AvailableDiarrhea / Immunosuppression1
Not AvailableRecruitingNot AvailableHepatocellular,Carcinoma / Neuroendocrine Tumors1
Not AvailableRecruitingHealth Services ResearchRoux-en-Y Bariatric Surgery1
Not AvailableRecruitingTreatmentAcromegaly1
Not AvailableRecruitingTreatmentGastroesophageal variceal hemorrhage prophylaxis1
Not AvailableRecruitingTreatmentPeriampullary Tumors1
Not AvailableTerminatedTreatmentPrader-Willi Syndrome1
Not AvailableUnknown StatusNot AvailableCancer, Breast1
Not AvailableUnknown StatusNot AvailableEsophageal and Gastric Varices / Hemorrhage / Liver Cirrhosis1
Not AvailableUnknown StatusBasic ScienceBMI >30 kg/m2 / General Surgery / Hypoglycemia1
Not AvailableUnknown StatusTreatmentAcromegaly1
Pharmacoeconomics
Manufacturers
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva parenteral medicines inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous; Subcutaneous100 ug/mL
InjectionIntravenous; Subcutaneous1000 ug/mL
InjectionIntravenous; Subcutaneous200 ug/mL
InjectionIntravenous; Subcutaneous50 ug/mL
InjectionIntravenous; Subcutaneous500 ug/mL
Injection, solutionIntravenous; Subcutaneous100 ug/mL
Injection, solutionIntravenous; Subcutaneous1000 ug/mL
Injection, solutionIntravenous; Subcutaneous200 ug/mL
Injection, solutionIntravenous; Subcutaneous50 ug/mL
Injection, solutionIntravenous; Subcutaneous500 ug/mL
SolutionIntravenous; Subcutaneous100 mcg
SolutionIntravenous; Subcutaneous500 mcg
SolutionIntravenous; Subcutaneous50 mcg
SolutionIntravenous; Subcutaneous200 mcg
PowderIntramuscular10 mg
PowderIntramuscular20 mg
PowderIntramuscular30 mg
Kit
Prices
Unit descriptionCostUnit
Sandostatin lar 30 mg kit3860.62USD kit
Sandostatin lar 20 mg kit2578.19USD kit
Sandostatin lar 10 mg kit1967.81USD kit
Sandostatin 1 mg/ml vial234.49USD ml
Sandostatin 0.5 mg/ml ampul111.48USD ml
Octreotide 1000 mcg/ml vial67.2USD ml
Sandostatin 0.2 mg/ml vial47.66USD ml
Octreotide acet 500 mcg/ml vial24.48USD ml
Sandostatin 0.1 mg/ml ampul23.11USD ml
Octreotide acet 100 mcg/ml vial15.36USD ml
Octreotide acet 200 mcg/ml vial14.4USD ml
Sandostatin 0.05 mg/ml ampul11.92USD ml
Octreotide acet 50 mcg/ml vial3.6USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5538739 No1993-07-232013-07-23Us
CA1328402 No1994-04-122011-04-12Canada
US5922338 Yes1997-01-132017-01-13Us
US5922682 Yes1997-01-132017-01-13Us
US5753618 Yes1995-11-192015-11-19Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP0.42ALOGPS
logP-1.4ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)11.4ChemAxon
pKa (Strongest Basic)10.17ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area332.22 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity269.77 m3·mol-1ChemAxon
Polarizability107.65 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9239
Blood Brain Barrier-0.8738
Caco-2 permeable-0.7824
P-glycoprotein substrateSubstrate0.8557
P-glycoprotein inhibitor INon-inhibitor0.9599
P-glycoprotein inhibitor IINon-inhibitor0.969
Renal organic cation transporterNon-inhibitor0.8506
CYP450 2C9 substrateNon-substrate0.8205
CYP450 2D6 substrateNon-substrate0.7632
CYP450 3A4 substrateNon-substrate0.5268
CYP450 1A2 substrateNon-inhibitor0.7975
CYP450 2C9 inhibitorNon-inhibitor0.7743
CYP450 2D6 inhibitorNon-inhibitor0.8449
CYP450 2C19 inhibitorNon-inhibitor0.7355
CYP450 3A4 inhibitorNon-inhibitor0.8236
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.708
Ames testNon AMES toxic0.6448
CarcinogenicityNon-carcinogens0.8761
BiodegradationNot ready biodegradable0.9943
Rat acute toxicity2.6174 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9693
hERG inhibition (predictor II)Inhibitor0.6064
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentOligopeptides
Alternative ParentsCyclic peptides / Phenylalanine and derivatives / N-acyl-alpha amino acids and derivatives / Macrolactams / Alpha amino acid amides / 3-alkylindoles / Amphetamines and derivatives / Aralkylamines / Substituted pyrroles / Fatty amides
SubstituentsAlpha-oligopeptide / Cyclic alpha peptide / Phenylalanine or derivatives / Macrolactam / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / Amphetamine or derivatives / 3-alkylindole / Indole
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Somatostatin receptor activity
Specific Function:
Receptor for somatostatin with higher affinity for somatostatin-14 than -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and Na(+)/H(+) exchanger via pertussis toxin insensitive G proteins.
Gene Name:
SSTR1
Uniprot ID:
P30872
Uniprot Name:
Somatostatin receptor type 1
Molecular Weight:
42685.77 Da
References
  1. Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma]. Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6. [PubMed:16438887 ]
  2. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L: Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004 Mar;79(3):142-8. Epub 2004 Apr 16. [PubMed:15103227 ]
  3. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. [PubMed:16625841 ]
  4. Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35. [PubMed:16625842 ]
  5. Ruan W, Fahlbusch F, Clemmons DR, Monaco ME, Walden PD, Silva AP, Schmid HA, Kleinberg DL: SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3? Mol Endocrinol. 2006 Feb;20(2):426-36. Epub 2005 Oct 13. [PubMed:16223973 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Somatostatin receptor activity
Specific Function:
Receptor for somatostatin 28 and to a lesser extent for somatostatin-14. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase. Increases cell growth inhibition activity of SSTR2 following heterodimerization.
Gene Name:
SSTR5
Uniprot ID:
P35346
Uniprot Name:
Somatostatin receptor type 5
Molecular Weight:
39201.925 Da
References
  1. Bronstein MD: Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. Front Horm Res. 2006;35:129-34. [PubMed:16809928 ]
  2. Xie Y, Tang CW, Wang CH: [Effect of HBV X gene transfection on octreotide-inhibited growth of hepatocellular carcinoma cell line HepG2]. Ai Zheng. 2005 Aug;24(8):965-9. [PubMed:16086874 ]
  3. Wang ZZ, Qu W, Wang F, Li Y, Wang SK, Wang JQ: [Expression of somatostatin receptor reporter gene and its correlation with targeted imaging in vivo for detection of pancreas carcinoma]. Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):663-6. [PubMed:16438887 ]
  4. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. [PubMed:16625841 ]
  5. Schmid HA, Silva AP: Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats. J Endocrinol Invest. 2005;28(11 Suppl International):28-35. [PubMed:16625842 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Somatostatin receptor activity
Specific Function:
Receptor for somatostatin-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase. In addition it stimulates phosphotyrosine phosphatase and PLC via pertussis toxin insensitive as well as sensitive G proteins. Inhibits calcium entry by suppressing voltage-dependent calcium channels. Acts as the functionally dominant somatostatin receptor i...
Gene Name:
SSTR2
Uniprot ID:
P30874
Uniprot Name:
Somatostatin receptor type 2
Molecular Weight:
41332.37 Da
References
  1. Yim CB, Boerman OC, de Visser M, de Jong M, Dechesne AC, Rijkers DT, Liskamp RM: Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. doi: 10.1021/bc900052n. [PubMed:19537708 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Uniprot Name:
Myeloperoxidase
Molecular Weight:
83867.71 Da
References
  1. Alatas E, Alatas O, Colak O: Octreotide inhibits myeloperoxidase activity in rat uterus. Acta Obstet Gynecol Scand. 2000 Jul;79(7):524-7. [PubMed:10929949 ]
  2. Alatas E, Gunal O, Alatas O, Colak O: Octreotide prevents postoperative adhesion formation by suppressing peritoneal myeloperoxidase activity. Hepatogastroenterology. 2000 Jul-Aug;47(34):1034-6. [PubMed:11020872 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:23